MML Investors Services
CGTX icon

MML Investors Services’s Cognition Therapeutics CGTX Stock Holding History

MML Investors Services’s Portfolio CGTX Stock Details CGTX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$11.5K Buy
10,018
+18
+0.2% +$21 ﹤0.01% 3248
2026
Q1 		$7.59K Hold
10,000
– – ﹤0.01% 2991
2025
Q4 		$13.5K Hold
10,000
– – ﹤0.01% 3029
2025
Q3 		$13.5K Buy
+10,000
New +$13.6K ﹤0.01% 2875

Other funds holding CGTX

BCM
BIOS Capital Management Fort Worth, Texas $41.7M AUM 34.92% 1-Year Est. Return
DC
Davenport & Co Richmond, Virginia $19.9B AUM 12.67% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
C
Chescapmanager Baltimore, Maryland $1.17B AUM 42.44% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $72.6B AUM 54.88% 1-Year Est. Return
HCM
Hilton Capital Management Garden City, New York $1.47B AUM 18.73% 1-Year Est. Return
Vanguard Fiduciary Trust
Vanguard Fiduciary Trust Malvern, Pennsylvania $454B AUM
CM
CM Management Gulf Breeze, Florida $157M AUM 60.08% 1-Year Est. Return

MML Investors Services's CGTX Position: Q2 2026 in Review

MML Investors Services increased its Cognition Therapeutics (CGTX) stake by 0.18% in Q2 2026, buying an estimated $21 and bringing the position to 10,018 shares worth $11.5K. The position accounts for ﹤0.01% of the portfolio, ranked #3248.

MML Investors Services first reported a position in CGTX in Q3 2025 and has held it in 4 quarters since. The position peaked at $13.5K in Q4 2025. 66 funds tracked by Wall St. Rank hold CGTX as of Q2 2026.

  • MML Investors Services held 10,018 shares of Cognition Therapeutics worth $11.5K as of Q2 2026.
  • MML Investors Services bought 18 Cognition Therapeutics shares in Q2 2026, an estimated $21.
  • Cognition Therapeutics made up ﹤0.01% of MML Investors Services's portfolio in Q2 2026, its #3248 holding.
  • MML Investors Services first reported a position in Cognition Therapeutics in Q3 2025 and has held it in 4 quarters since.
  • MML Investors Services's Cognition Therapeutics position peaked at $13.5K in Q4 2025.
  • 66 funds tracked by Wall St. Rank held Cognition Therapeutics as of Q2 2026.

Based on MML Investors Services's 13F filing for Q2 2026, filed 7 Aug 2026.